Featured Content & Success Stories

Obsidio - LSI Alumni - Acquired by Boston Scientific (August 2022)

Ehsan Jabbarzadeh is the CEO of Obsidio which was a presenting company at the LSI Emerging Medtech Summit in 2020. LSI is a proud supporter of Obsidio’s mission to innovate interventional medicine therapies using a unique hydrogel platform technology.

Biorez - LSI Alumni - Acquired by CONMED (August 2022)

Kevin Rocco is the CEO of Biorez and was a presenting company for the LSI Emerging Medtech Summit in 2020, 2021, & 2022. LSI is a proud supporter of Biorez and its commitment to helping patients return to full activity sooner and safer following debilitating ligament and tendon injuries. 

Biorez is an early-stage medical device company, developing bio-inductive implants for the $7B sports medicine market that help restore joint stability and aid in the direct healing and regeneration of new functional tissue.

Medtronic Announces co-promotion agreement with Cathworks, with path toward acquisition (July 2022)

Ramin Mousavi is the President and CEO of Cathworks, which was a presenting company for the LSI Emerging Medtech Summit in 2020. LSI is a proud supporter of Cathworks and its mission of partnering with physicians to improve the health of patients by transforming how cardiovascular disease is diagnosed and treated. 

Cathworks is a software solutions focused on improving the utilization of coronary angiography data to ratify measurement-based medicine in the cath lab.

Materna Medical - LSI Alumni - Raises $20 Million Series B Financing (August 2022)

Tracy MacNeal is the President and CEO of Materna Medical, which was a presenting company for the LSI Emerging Medtech in 2022. LSI is a proud supporter of Materna Medical's mission to empowering women to protect and restore their pelvic health.

Materna Medical is developing solutions to improve pelvic health in women. The company's first product, Milli, is designed to addressed pelvic pain in the general population. Materna is currently developing a second product designed to expedite labor and reduce pelvic damage during the initial stage of labor.

Galen Robotics - LSI Alumni - Raises $15 Million Series A (October 2022)

Bruce Lichorowic is the President & CEO of Galen Robotics which was a presenting company at the LSI Emerging Medtech Summit in 2021 and 2022. LSI is a proud supporter of Galen Robotics’s mission to filling gaps left by other surgical robotic technologies, with a focus on unserved applications in microsurgery, digital surgery, and robotic surgery.

Galen Robotics' aim is to make surgeon’s lives easier through assistive technology in the operating room. To fulfill that vision, the company has developed a surgical robotic platform intended to fill unserved needs in the current surgical robotics market, including neurosurgery, otolaryngology, tissue reconstruction, intrauterine brain, and spine surgery.

Day Zero Diagnostics - LSI Alumni - Awarded $8.2 Million (October 2022)

Jong Lee is the CEO of Day Zero Diagnostics which was a presenting company at the LSI Emerging Medtech Summit in 2021 and 2022. LSI is a proud supporter of Day Zero Diagnostics’s mission to revolutionizing infectious disease diagnosis and treatment with genomic sequencing and machine learning to solve antibiotic resistance.

Day Zero Diagnostics is harnessing the power of the genome to build technologies that both precisely identify the species and provide the comprehensive antibiotic susceptibility / resistance profile of a bacterial infection within hours, rather than days, so that patients can be treated with the most effective antibiotic quickly.

FineHeart - LSI Alumni - Set to Receive £17.5 Million (October 2022)

Arnaund Mascarell is the Founder & CEO of FineHeart which was a presenting company at the LSI Emerging Medtech Summit 2020. LSI is a proud supporter of FineHeart's mission to address the unmet need of patients with severe heart failure. 

FineHeart is a French medical device company focused on creating innovative technologies in the cardiovascular field. The patented FineHeart invention, the I.C.O.M.S. (Implantable Cardiac Output Management System), is a novel, wirelessly powered, fully implantable mechanical circulatory support device that is able to optimize cardiac output while preserving the heart’s innate contractility.

Otolith Labs - LSI Alumni - Raises $20M Series A Financing (September 2022)

Sam Owen is the CEO of Otolith Labs and was a presenting company for the LSI USA '22 Emerging Medtech Summit. LSI is a proud supporter of Otolith Labs and its mission to pioneer the first medical wearable for the treatment of chronic vertigo, a symptom experienced by 4-5 million Americans.

Otolith is developing a wearable device for the treatment of vertigo. The device delivers a precise level of mechanical stimulation to the acceleration sensors of the inner ear. The therapeutic vibration masks vertiginous signals from the vestibular system to alleviate vertigo symptoms.

Synergia Medical - LSI Alumni - Raises €9M Series B Financing (September 2022)

Attila Borbath is CEO & Co-Founder of Synergia Medical and was a presenting company for the LSI Emerging Medtech Summit in 2022 and 2021. LSI is a proud supporter of Synergia Medical and its goal to develop a technological platform which could benefit the next generation neurostimulation devices.

Synergia Medical is leveraging photonics to create a platform for small, safe and long-lasting neurostimulators.

Levita Magnetics - LSI Alumni - Raises $26M Series C Financing (August 2022)

Alberto Rodriguez-Navarro is the Founder, President, & CEO of Levita Magnetics, which was a presenting company for the LSI USA Emerging Medtech in 2022. LSI is a proud supporter of Levita Magnetics' mission to enhance patient outcomes by minimizing the footprint of surgical procedures across multiple indications and broad patient populations.

Levita Magnetics is committed to improving patient outcomes and quality of life through Magnetic Surgery®, the next step in the evolution of minimally invasive surgery. This innovative technology platform minimizes the footprint of surgery by decreasing the number of incisions and trocars needed in surgical procedures for better cosmetic outcomes.

FundamentalVR - LSIAlumni - Raises $20M in Series B Financing (August 2022)

Richard Vincent is the Founder & CEO of FundamentalVR and was a presenting company for the LSI Emerging Medtech Summit in 2021, & 2022. LSI is a proud supporter of FundamentalVR and its mission to accelerate the surgical capability for life science businesses via precision VR simulation. 

FundamentalVR is a deep IP company working at the intersection of immersive technology (XR), haptics and machine learning. It is the company's belief that immersive technology has the ability to change the human/computing interface forever, to transcend geographies and accelerate business.

Inovus Medical Completes $7 Million Investment Round (May 2022)

Elliot Street is the co-founder and CEO of Inovus Medical, which was a presenting company for the LSI Emerging Medtech in 2022. LSI is a proud supporter of Inovus' mission to become the worlds partner for surgical training. 

Inovus Medical is a designer and manufacturer of medical simulation products that provide teaching skills in critical care, medicine hysteroscopic and general surgery.

Bardy Acquired by Hill-Rom (August 2021)

Ken Nelson is the Chief Commercial Officer for Bardy Diagnostics and is an LSI Alumni innovator who presented at the LSI Emerging Medtech Summit in 2020. LSI is a proud supporter of Bardy Diagnostics and its mission to improve clinical management and outcomes for patients and their physicians by employing innovative P-wave centric ECG detection into patient-friendly technologies that result in greater patient compliance and more confident physician diagnoses.

Bardy Diagnostics is an innovator in digital health and remote patient monitoring, with a focus on providing the most diagnostically-accurate and patient-friendly cardiac patch monitors to the industry, including the award-winning Carnation Ambulatory Monitor (CAM™) patch.

Centerline Biomedical Raises $33 million in series B financing (June 2022)

Philip Rackliffe is the CEO of Centerline Biomedical, which was a presenting company at LSI Emerging Medtech Summit in 2020, 2021, and 2022. LSI is a proud supporter of Centerline Biomedical's mission to provide navigation technology to reduce radiation exposure and improve accuracy. 

Centerline Biomedical provides a surgical navigation system designed to reduce radiation exposure to patients and caregivers during endovascular procedures

SpinTech MRI Announces $6.5 million Series A Financing (July 2022)

Karen Holzberger is the President & CEO of SpinTech MRI, which was a presenting company at LSI Emerging Medtech Summit in 2022. LSI is a proud supporter of SpinTech MRI's mission to to push the boundaries of what is possible with MRI technology by transforming advanced research techniques into practical clinical application. 

SpinTech MRI is an essential MRI technology partner. Through rapid, quantitative brain imaging software, STAGE images may provide information useful in determining diagnosis when interpreted by a trained physician

Avenda Health - LSI Alumni - Raises $10 Million Series B Financing (August 2022)

Shyam Natarajan is CEO of Avenda Health, which was a presenting company for the LSI Emerging Medtech in 2021. LSI is a proud supporter of Avenda Health's mission to create a more personalized future of prostate cancer care.

Avenda uses AI deep learning (via its iQuest software) to help surgeons identify precisely where the tumor lies within the gland and the extent of the disease to target cancerous tissue only - leaving everything else untouched.

Altoida - LSI Alumni - Raises $20.3M Series A (March 2022)

Travis Bond is CEO of Altoida and was a presenting company at LSI USA '22 Emerging Medtech Summit. LSI is a proud supporter of Altoida and its mission of pioneering precision neurology by building the world's leading platform for reliable, accessible, affordable diagnosis and monitoring of neurological diseases.

Altoida’s technology platform uses artificial intelligence (AI) to analyze cognitive and functional test results and help diagnose neurological diseases, like Mild Cognitive Impairment (MCI) and Alzheimer’s. The proprietary 10-minute set of digital test activities (completed on a smartphone or tablet) use augmented reality (AR) to simulate real-world activities of daily living, enabling changes in cognition and function to be captured earlier and more accurately than existing methods. The platform has received FDA Breakthrough Device Designation.

Onkos Surgical Receives FDA 510(k) Clearance for 3D Printed, Patient-Specific Pelvic Reconstruction System (June 2022)

Patrick Treacy is the CEO of Onkos Surgical which was a presenting company for the LSI Emerging Medtech Summit in 2021 & 2022. LSI is a proud supporter of Onkos Surgical's mission to provide a surgeon-driven and patient-inspired approach to musculoskeletal cancer and complex conditions.

Onkos Surgical is a leader in innovative solutions for musculoskeletal oncology and complex orthopaedic procedures. With their Precision Orthopaedics approach, surgeons are better informed about patient-specific clinical challenges and are able to plan and implement a more precise reconstruction. Their personalized approach supports improved patient outcomes and experiences using the latest innovations in virtual surgical planning, 3D modeling and printing, implant design, and workflow optimization.

Retia Medical Raises $15 Million to Accelerate Commercialization of the Argos Hemodynamic Monitor

Marc Zemel is the CEO and Co-Founder of Retia Medical which was a presenting company for the LSI Emerging Medtech Summit in 2021 & 2022. LSI is a proud supporter of Retia Medical's mission to provide technology that provides high-quality hemodynamic data clinicians need to quickly and appropriately respond to changes in patient status when time matters most.

Retia makes advanced hemodynamic monitors using the patented Multi-Beat Analysis MBA™ algorithm to guide care for high-risk surgical and ICU patients. Using the data from our monitor, clinicians implement proven protocols that reduce acute kidney injuries, myocardial injuries and other costly complications.

Osso VR - LSI Alumni - Raises $66M Series C (March 2022)

Justin Barad is Founder & CEO of Osso VR and was a presenting company at LSI USA '22 Emerging Medtech Summit. LSI is a proud supporter of Osso VR and its mission of enabling device companies and medical teams to practice together from anywhere, and empower themselves to grow with accurate assessment and insightful data. 

Osso VR is an award winning VR surgical and medical device training platform. The company is made up of practicing clinicians, professional VR developers and medtech industry veterans. The comany specializes in hyper-realistic, haptic-enhanced, hands-on interactivity and design.

restor3d - LSI Alumni - Raises $23M (April 2022)

Ken Gall is Founder & CTO of restor3d and was a presenting company at LSI USA '22 Emerging Medtech Summit. LSI is a proud supporter of restor3d and its mission of enabling surgeons to improve the reconstruction and repair of the human body through 3D printed implants with enhanced anatomical fit and superior integrative properties.

restor3d, a leading medical device company and 3D printing manufacturer, has raised $23 million to expand the delivery of 3D printed personalized surgical solutions across multiple musculoskeletal specialties and to develop machine learning software tools for assisting engineers with patient specific implant design.

Virtual Incision - LSI Alumni - Closed Series C (November 2021)

John Murphy is CEO of Virtual Incision and has been selected as a presenting company for the LSI Emerging Medtech Summit in 2021. John led his company to a successful capital raise close in November 2021. LSI is a proud supporter of Virtual Incision and its mission to offer mobility, flexibility, and accessibility to minimally invasive (MIS) procedures.

The company is developing the MIRA® (Miniaturized In vivo Robotic Assistant) Platform, a first-of-its-kind miniaturized surgical robotic support device, focusing first on colon resection, with follow-on specialty robots for additional potential applications. The company is headquartered in Lincoln, Nebraska.

Explorer Surgical - LSI Alumni - Acquired (October 2021)

Jennifer Fried is CEO of Explorer Surgical and has been selected as a presenting company for the LSI Emerging Medtech Summits in 2020 and 2021.  Jennifer led her company to a successful exit in October 2021.  LSI is a proud supporter of Explorer Surgical and its mission to demystify the black box of the operating room.

Explorer Live is a digital case support platform connecting medical device teams to providers enabling them to remotely share best practices and collaborate in real-time during a live procedure. Explorer Live is tailored for providers to reduce procedure variability and minimize learning curves.

"Medtech is the best and original impact investment"

Chris is a prolific entrepreneur and venture capitalist who has pioneered some of the most innovative medical technologies brought to market in the last decades. As Founder and Executive Chairman of Miraki  Innovation, Chris forecasts imminent global health and medical challenges, uncovers technologies  at leading research institutions and assembles teams of industry experts to solve these global problems.  

Companies developed by Chris have created considerable value. Investments, returns and valuations from seven companies founded, developed and/or brought to exit by Chris have benefited from more than $5.77 billion in returns realized to all investors through exits. A recent example is Auris Health which was recognized by CNBC as one of the 50 most disruptive companies in the world. The Auris transaction was proceeded by a number of ventures by Chris that set gold standard for motion preservation, regeneration of cartilage and soft tissue through the use of novel peptides and regenerative medicine. Throughout his 27-year career, Chris has represented more than 150 medical device companies in a variety of business transactions including licensing agreements, joint venture partnerships and M&A.

"Regulation A+ is the 21st Century way to raise capital"

Manny Villafaña, PhD, Sc, has a substantial track record starting companies that develop and deliver successful products to the market.

• Cardiac Pacemakers, Inc. (CPI) revolutionized the pacemaker industry by introducing a long-life lithium iodine pacemaker, a technology still used today by 100% of the pacemaker/defibrillator market. CPI is now owned by Boston Scientific.
• St. Jude Medical developed an innovative, mechanical, bi-leaflet heart valve that dramatically reduced the frequency of blood clots. St. Jude is now part of Abbott Medical.
• ATS Medical further evolved the mechanical heart valve, introducing an open-pivot design and capturing a strong share of the market. ATS is now owned by Medtronic.

As a result, Manny has received numerous awards of recognition, including:

• The "Living Legend of Medicine" award from the World Society of CardioThoracic Surgeons.
• MDEA Lifetime Achievement Award.
• Inductee of the Minnesota Business Journal Hall of Fame and the Minnesota Science and Technology Hall of Fame.

Medtech Capital and the New Frontier from the Father of the JOBS Act

David Weild IV, is Founder, Chairman, and CEO of Weild & Co and former Vice Chairman of NASDAQ. He is recognized as the “father” of the JOBS Act and regarded as one the world’s top experts on capital markets and capital formation.

Manny Villafaña, PhD, Sc, Awarded '2022 Lifetime Achievement Award in Medical Devices'

At LSI USA '22 Emerging Medtech Summit, Manny Villafaña, was awarded, the '2022 Lifetime Acheivement Award in Medical Devices.' 

Manny has a substantial track record starting companies that develop and deliver successful products to the market.

• Cardiac Pacemakers, Inc. (CPI) revolutionized the pacemaker industry by introducing a long-life lithium iodine pacemaker, a technology still used today by 100% of the pacemaker/defibrillator market. CPI is now owned by Boston Scientific.
• St. Jude Medical developed an innovative, mechanical, bi-leaflet heart valve that dramatically reduced the frequency of blood clots. St. Jude is now part of Abbott Medical.
• ATS Medical further evolved the mechanical heart valve, introducing an open-pivot design and capturing a strong share of the market. ATS is now owned by Medtronic.

As a result, Manny has received numerous awards of recognition, including:

• The "Living Legend of Medicine" award from the World Society of CardioThoracic Surgeons.
• MDEA Lifetime Achievement Award.
• Inductee of the Minnesota Business Journal Hall of Fame and the Minnesota Science and Technology Hall of Fame.

Cala Health - LSI Alumni - Raised $77M (November 2021)

Renee Ryan is CEO of Cala Health and has been selected as a presenting company for the LSI Emerging Medtech Summit in 2021. Renee led her company to a successful funding round in November 2021. LSI is a proud supporter of Cala Health and its mission to transform the standard of care for chronic disease.

Cala Health’s lead product, Cala Trio™, is the only non-invasive prescription therapy for essential tremor. New therapies are under development in neurology, cardiology and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.

New View Surgical - LSI Alumni - Closed Series B (September 2021)

Bryce Klontz is President & CEO of New View Surgical and has been selected as a presenting company for the LSI Emerging Medtech Summits in 2020 and 2021. Bryce led his company to a successful capital raise close in November 2021 and they continue to hit other key milestones under his leadership. LSI is a proud supporter of View Surgical and its mission to improve the outcomes and efficiency of laparoscopic surgical procedures through the introduction of their VisionPort™ technology.

New View Surgical is a Minimally Invasive Surgery (MIS) company focused on improving the outcomes of laparoscopic surgical procedures through the commercialization of clinically and economically superior visualization technologies. The innovative VisionPort will simplify minimally invasive procedures, give surgeons greater control, improve safety and enhance technical proficiency.

PAVmed - LSI Alumni - NASDAQ IPO

Lishan Aklog is Chairman, CEO, & Co-Founder of PAVmed and CEO of Lucid Diagnostics. He has been selected as a presenting company for the LSI Emerging Medtech Summits in 2020 and 2021. Lishan led his company to a successful IPO in October 2021. LSI is a proud supporter of Lucid Diagnostics and its mission to empower clinicians to save lives by accurately detecting Barrett’s Esophagus (BE).

Lucid Diagnostics is a highly differentiated, medical device innovator with products designed to diagnose and treat conditions of the esophagus, including conditions arising from chronic heartburn which may lead to esophageal cancer. Lucid Diagnostics is developing a revolutionary technology such as a non-invasive, office-based targeted cell collection device (EsoCheck) and a lab-based, DNA biomarker test (EsoGuard) to detect the precursor condition (Barrett’s Esophagus or BE) to highly lethal esophageal cancer.

Vicarious Surgical - LSI Alumni - $1.1B SPAC Deal

Adam Sachs is CEO of Vicarious Surgical and has been selected as a presenting company for the LSI Emerging Medtech Summit in 2021. Adam led his company to a successful $1.1B SPAC deal. LSI is a proud supporter of Vicarious Surgical and its mission to bring robotics and virtual reality to minimally invasive surgery.

Vicarious Surgical has reimagined what is possible by building a human-like surgical robot and combining it with the world’s first virtual-reality surgical camera to allow surgeons to perform minimally-invasive surgery with the ease of an open procedure.

EBR Systems - LSI Alumni - ASX IPO (November 2021)

John McCutcheon is President & CEO of EBR Systems and has been selected as a presenting company for the LSI Emerging Medtech Summit in 2021. John led his company to a successful IPO in November 2021. LSI is a proud supporter of EBR Systems and its mission to deliver superior treatment for millions of patients suffering from cardiac rhythm diseases.

The company’s initial product, the WiSE™ CRT System, is a first-of-its-kind medical device developed to overcome the limitations of traditional Cardiac Resynchronization Therapy (CRT) in heart failure patients by eliminating the need for a lead to the heart’s left ventricle and the associated complications of that lead. 

Catalyst OrthoScience - LSI Alumni - Closed Series D (October 2021)

Brian Hutchison is CEO of Catalyst OrthoScience and has been selected as a presenting company for the LSI Emerging Medtech Summit in 2021. Brian led his company to a successful capital raise close in October 2021. LSI is a proud supporter of Catalyst OrthoScience and its mission to develop innovative medical solutions that make orthopedic surgery less invasive and more efficient for both surgeons and patients.

Catalyst OrthoScience is a medical device company focused on the upper extremity orthopedics market. Catalyst OrthoScience was founded by a board-certified orthopedic surgeon and consists of a team of biomedical industry professionals with more than 100 years of combined medical device experience.

Anavasi Diagnostics - LSI Alumni - NIH Awarded Funding (November 2021)

Nelson Patterson is President & CEO of Anavasi Diagnostics and has been selected as a presenting company for the LSI Emerging Medtech Summit in 2021. Anavasi was awarded funding by NIH in November 2021. LSI is a proud supporter of Anavasi Diagnostics and its mission to enable health care professionals to confidently provide lab-quality results in minutes instead of days.

Anavasi Diagnostics’ product the AscencioDx™ molecular detection platform, is now in clinical testing and is designed to provide a precise diagnosis of COVID-19 in under 30-minutes (on average) instead of the 1-3 days that most testing services and physician offices now require for PCR testing.

HAPPE Spine - LSI Alumni - Closed Series A (November 2021)

Ryan Roeder is Founder & CTO at HAPPE Spine and has been selected as a presenting company for the LSI Emerging Medtech Summits in 2020 and 2021. Ryan led his company to a successful capital raise close in August 2021. LSI is a proud supporter of HAPPE Spine and its mission to provide an ideal implant material solution for interbody spinal fusion.

HAPPE Spine’s Hydroxyapatite PEEK (HAPPE), is an ideal implant material solution for interbody spinal fusion.

Alio Raises $20 Million in Series B Financing (June 2021)

David Kuraguntla is the CEO of Alio, which was a presenting company for the LSI Emerging Medtech Summit in 2021 & 2022. LSI is a proud supporter of Alio's mission to provide noninvasive remote monitoring for complications in dialysis patients, providing actionable data at the right time in one place. 

Alio's SmartPatch is a discrete patch that continuously monitors and tracks vitals, including O2 saturation, temperature, blood pressure, and more. 

Coala Life - LSI Alumni - IPO

Philip Siberg is Co-Founder, Chief Strategy Officer, & Head of IR at Coala Life and has been selected as a presenting company for the LSI Emerging Medtech Summit in 2020. Philip led his company to a successful IPO in September 2021. LSI is a proud supporter of Coala Life and its mission to develop solutions that aim to digitally transform the field of cardiac diagnostics that help win the battle against the world’s leading cause of death - heart disease.

Coala Life (Nasdaq First North: COALA) is a Swedish medical technology and life science company focusing on heart diagnostics and digital health. Coala aims to replace the stethoscope with a digital solution that records both heart sounds, ECG, and heart frequency.

Delphinus Medical Technologies - LSI Alumni - FDA Approval

Mark Forchette is President & CEO of Delphinus Medical Technologies and has been selected as a presenting company for the LSI Emerging Medtech Summit in 2021. Mark led his company to a successful premarket FDA approval in October 2021. LSI is a proud supporter of Delphinus Medical Technologies and its mission to transform early detection of breast cancer and save women’s lives all over the world.

Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a ring transducer to transmit and receive ultrasound signals. The SoftVue™ system captures reflection echoes from all directions around the breast and gathers transmitted signals coming through the breast. 

270Surgical - LSI Alumni - FDA Clearance

Chad Croasdale is President & CCO of 270Surgical and has been selected as a presenting company for the LSI Emerging Medtech Summit in 2021. Chad led his company to successful FDA Clearance in November 2021. LSI is a proud supporter of 270Surgical and its mission to advance visual intelligence to provide novel insights and better patient care.

270Surgical’s SurroundScope™ visual intelligence offers an entirely new approach to minimally invasive surgery, eliminating the challenges posed by current technologies such as tunnel vision, lens fogging, camera shaking, and visual obstruction caused by smoke.

Strados Labs - LSI Alumni - Closed Pre-Series A Financing Round

Nick Delmonico is CEO of Strados Labs and has been selected as a presenting company for the LSI Emerging Medtech Summits 2020 & 2021. Nick led his company to a successful $4.5M Pre-Series A round of funding. LSI is a proud supporter of Strados Labs and its mission to give patients a better quality of life by giving doctors and patients remote access to lung sounds and respiratory patterns. 

Strados Labs is a medical technology company that specializes in advancing respiratory health management using clinical-grade biosensors and intelligent software. Their top priority is to assist medical professionals in the monitoring and management of pulmonary conditions through innovative medical devices that reduce the probability of loss of control of airway disease.

Nanochon - LSI Alumni - Closed Seed Round

Benjamin Holmes is CEO of Nanochon and has been selected as a presenting company for the LSI Emerging Medtech Summits 2020 & 2021. Ben led his company to a successfully Closed Seed Round in September 2021. LSI is a proud supporter of Nanochon and its mission to develop an implant that replaces lost and damaged cartilage as well as encourages new tissue growth. 

Nanochon is developing an implant designed to not only replace lost and damaged cartilage, but also to encourage new tissue growth. Using 3-D printing and a novel material, the Nanochon implant is a sturdy medical advancement that is both an orthopedic load bearing implant as well as a tissue growth scaffold. The Nanochon implant has the potential to deliver faster and more successful recoveries for patients, while reducing costs to health providers, payers, and patients. Nanochon’s aim is to set a new clinical standard for cartilage restoration.

Pixium Vision - LSI Alumni - First Successful Implantation in PRIMAvera Study in UK

Lloyd Diamond is CEO of Pixium Vision and has been selected as a presenting company for the LSI Emerging Medtech Summit 2021. Lloyd led his company to the first successful implantation in PRIMAvera Study in the UK. LSI is a proud supporter of Pixium Vision and its mission to provide best in class bionic vision restoration systems enabling the blind to regain greater autonomy and improved quality of daily living.

Pixium Vision, created in December 2011, is a bioelectronics and brain machine interface technology company specialized in neuromodulation application whose mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy.

Embody, Inc. Announces $20.5 million Funding Round (August 2021)

Jeff Conroy is the CEO of Embody and was a presenter at the LSI Emerging Medtech Summit in 2020 & 2022. LSI is a proud supporter of Embody's mission to improve quality of life for traumatic and sports injury patients by providing regenerative products that promote faster healing and restore pre-injury performance.

Embody is pioneering the next generation in soft tissue healing with novel collagen-based biofabrication techniques and biologic products for tissue healing. Founded in 2014, the company continues to develop unique biomaterials providing healing solutions for challenging orthopedic procedures including foot and ankle, rotator cuff, and knee ligament.

Shoulder Innovations Closed $21.5 Million Series C (November 2020)

Matt Ohearn is the COO of Shoulder Innovations, which was a presenting company for the LSI Emerging Medtech Summit in 2020, 2021, & 2022. LSI is a proud supporter of Shoulder Innovation's mission to improve procedure logevity ultimately changing patient's lives.

Shoulder Innovations is a total shoulder replacement system that addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant.

INBRAIN Neuroelectronics - LSI Alumni - Receives €17.5 Million From European EIC Accelerator (December 2022)

Carolina Aguilar is the CEO of INBRAIN Neuroelectronics, which was a presenting company for the LSI Europe Emerging Medtech Summit in 2022. LSI is a proud supporter of INBRAIN Neuroelctronics' mission to decode neural signals to restore patients’ lives

INBRAIN Neuroelectronics' Graphene core technology designed to decode brain signals into medical solutions in the field of neuroelectronic therapies with the objective to restore patients' quality of life in those affected with brain-origin disorders. The company is developing a minimally invasive neural interface which will initially serve patients with epilepsy and Parkinson's disease.

Moon Surgical secures FDA 510(k) clearance for its Maestro Surgical Robotic System

Anne Osdoit is the CEO of Moon Surgical which was a presenting company at the LSI Europe Emerging Medtech Summit in 2022. LSI supports Moon Surgical in their mission of developing a surgical robot to assist with laparoscopic surgeries, using a system that will feature a modular platform, computer vision, and haptics to augment the capabilities of surgeons. 

Alio Raises $18M in First Close of Series C Financing

David Kuraguntla is the CEO/Co-Founder of Alio (fka GraftWorx) which was a presenting company at the LSI Emerging Medtech Summit in 2021 and 2022, and will be in 2023 as well. LSI is proud to support Alio and their SmartPatch, which is a discrete patch that continuously monitors and tracks vitals, including O2 saturation, temperature, blood pressure, and more.

This funding comes on top of a previous $20M earlier in the year, and shines a bright future on Alio.

CardiaCare - LSI Alumni - Announces Licensing and Distribution Agreement to Commercialize its Digital Neuromodulation Wearable (December 2022)

Amos Ziv is the Founder & CSO of CardiaCare, which was a presenting company for the LSI Europe Emerging Medtech Summit in 2022. LSI is a proud supporter of CardiaCare's mission to create a non-invasive personalized neuromodulation therapy for Atrial Fibrillation.

Cardia Care has created the world's first home-care therapy delivery and real time monitoring system for people with atrial fibrillation.

Activ Surgical Secures CE Mark Approval for ActivSight Intelligent Light

Ehsan Jabbarzadeh is the CEO of Obsidio which was a presenting company at the LSI Emerging Medtech Summit in 2020 and the Europe event in 2022. Activ Surgical's imaging hardware and software to improve surgical outcomes is encouraging for the future of surgery, and is proudly supported by LSI.

The company utilizes AI, near-infrared fluorescent imaging, and robotics to enhance surgical vizualition and navigation beyond what is visible from traditional imaging systems (e.g. endoscopy).  

Endoron Medical - LSI Alumni - Awarded €2.5 Million Grant (December 2022)

Ronit Harpaz is the Co-Founder & CEO of Endoron Medical, which was a presenting company for the LSI Europe Emerging Medtech Summit in 2022. LSI is a proud supporter of Endoron Medical's mission to create an endograft fastening solution for complete seal and stablity.

Endoron is developing a long-lasting solution for the treatment of abdominal aortic aneurysm (AAA). The company's Aortoseal system uses a smart stapling system that penetrates the aortic wall and stent graft to secure the graft in place in a variety of anatomies. 

Nyra Medical Raises $20M Series A

Murali Padala is the Founder and CEO of Nyra Medical, which was a presenting company for the LSI Emerging Medtech Summit in 2022. LSI is a proud supporter of Nyra Medical and their image-guided, catheter-based intervention, called the cardiac leaflet enhancer (CARLEN), for the treatment of mitral and/or tricuspid regurgitation in heart failure patients. 

Their mission is to develop a first in class transcatheter valve repair technology.

Delphinus Raises $30M in Series D Funding

Mark Forchette is the President and CEO of Delphinus Medical Technologies, which was a presenting company for the LSI Emerging Medtech Summit in 2021 and 2022, and will present at 2023 as well. LSI is a proud supporter of Delphinus and its mission to improve breast cancer screenings and treatment.

The patented technology is a 3D whole breast ultrasound imaging device that delivers no radiation, requires no compression, and images the entire breast with a single scan. 

New View Surgical Closes $12.1M Series B-1

Bryce Klontz is the President and CEO of New View Surgical, which was a presenting company for the LSI Emerging Medtech Summit in 2020, 2021, and 2022. LSI is a proud supporter of New View Surgical and its mission of increasing access to minimally invasive techniques for patients around the world.

Cathworks is developing proprietary imaging and access technologies for minimally invasive surgery.

Nutromics Raises $14M

Co-Founder's Peter Vranes and Hitesh Mehta of Nutromics, which was a presenting company for the LSI Emerging Medtech Summit in 2020, 2021, and 2022. LSI is a proud supporter of Nutromics and pioneering Continuous Molecular Monitoring (CMM), a real-time biomarker monitoring platform that offers molecular patient data.

Nutromics is on a mission to revolutionize healthcare and improve patient care.